Nuclear factor-κB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia

British Journal of Haematology

Volumn 143, Issue 5, 2008, Pages 661-671

  Jenkins, Christopher ^a   Hewamana, Saman ^a   Gilkes, Amanda ^a   Neelakantan, Sundar ^b   Crooks, Peter ^b   Mills, Ken ^c   Pepper, Chris ^a   Burnett, Alan ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b University of Kentucky   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Cytokines; Nuclear factor B; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LC 1; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG; LC 1 COMPOUND; LC-1 COMPOUND; SESQUITERPENE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL PROTECTION; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; GENETIC RISK; HUMAN; HUMAN CELL; LD 50; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CLASSIFICATION; CYTOTOXICITY TEST; DNA MICROARRAY; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYTOTOXICITY TESTS, IMMUNOLOGIC; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SESQUITERPENES; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 55949105242     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07392.x     Document Type: Article

References (49)

1. Aribi, A., Ravandi, F. Giles, F. (2006) Novel agents in acute myeloid leukaemia. Cancer Journal, 12, 77 91.
2. Barbarroja, N., Arístides-Torres, L., Hernandez, V., Martín, C., Dorado, G., Torres, A., Velasco, F. Lopez-Pedrera, C. (2007) Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leukemia and Lymphoma, 48, 1187 1199.
3. Baumgartner, B., Weber, M., Quirling, M., Fischer, C., Page, S., Adam, M., Von Schilling, C., Waterhouse, C., Schmid, C., Neumeier, D. Brand, K. (2002) Increased I kappa B kinase activity is associated with activated NF-kappa B in acute myeloid blasts. Leukaemia, 16, 2062 2071.
4. Bentires-Alj, M., Barbu, V., Fillet, M., Chariot, A., Relic, B., Jacobs, N., Gielen, J., Merville, M.P. Bours, V. (2003) NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 22, 90 97.
5. Bharti, A.C., Shishodia, S., Reuben, J.M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M. Aggarwal, B.B. (2004) Nuclear factor-kappa B and STAT3 are constitutively active in CD138(+) cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood, 103, 3175 3184.
6. Birkenkamp, K.U., Geugien, M., Schepers, H., Westra, J., Lemmink, H.H. Vellenga, E. (2004) Constitutive NF-kappa B DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukaemia, 18, 103 112.
7. Blackwell, T.S. Christman, J.W. (1997) The role of nuclear factor-kappa B in cytokine gene regulation. American Journal of Respiratory Cell and Molecular Biology, 17, 3 9.
8. Braun, T., Carvalho, G., Coquelle, A., Vozenin, M.C., Lepelley, P., Hirsch, F., Kiladjian, J.J., Ribrag, V., Fenaux, P. Kroemer, G. (2006a) NF-kappa B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood, 107, 1156 1165.
9. Braun, T., Carvalho, G., Fabre, C., Grosjean, J., Fenaux, P. Kroemer, G. (2006b) Targeting NF-kappa B in hematologic malignancies. Cell Death and Differentiation, 13, 748 758.
10. Bueso-Ramos, C.E., Rocha, F.C., Shishodia, S., Medeiros, L.J., Kantarjian, H.M., Vadhan-Raj, S., Estrov, Z., Smith, T.L., Nguyen, M.H. Aggarwal, B.B. (2004) Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukaemia. Human Pathology, 35, 246 253.
11. Cusack, Jr., J.C., Liu, R., Houston, M., Abendroth, K., Elliott, P.J., Adams, J. Baldwin, Jr., A.S. (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappa B inhibition. Cancer Research, 61, 3535 3540.
12. Dubois, C., Schlageter, M.H., de Gentile, A., Balitrand, N., Toubert, M.E., Krawice, I., Fenaux, P., Castaigne, S., Najean, Y. Degos, L. (1994) Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukaemia. Leukaemia, 8, 1750 1757.
13. Duyao, M.P., Buckler, A.J. Sonenshein, G.E. (1990) Interaction of an NF-kappa-B-like factor with a site upstream of the C-Myc promoter. Proceedings of the National Academy of Sciences of the United States of America, 87, 4727 4731.
14. Estrov, Z., Manna, S.K., Harris, D., Van, Q., Estey, E.H., Kantarjian, H.M., Talpaz, M. Aggarwal, B.B. (1999) Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukaemia cells. Blood, 94, 2844 2853.
15. Frelin, C., Imbert, V., Griessinger, E., Peyron, A.C., Rochet, N., Philip, P., Dageville, C., Sirvent, A., Hummelsberger, M., Bérard, E., Dreano, M., Sirvent, N. Peyron, J.F. (2005) Targeting NF-kappa B activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukaemia cells. Blood, 105, 804 811.
16. Frostad, S. Bruserud, O. (1999) In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukaemia blasts. European Journal of Haematology, 62, 191 198.
17. Fu, L., Lin-Lee, Y.C., Pham, L.V., Tamayo, A., Yoshimura, L. Ford, R.J. (2006) Constitutive NF-kappa B and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood, 107, 4540 4548.
18. Ghosh, S., May, M.J. Kopp, E.B. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology, 16, 225 260.
19. Gilmore, T.D. (1997) Introduction: the Rel/NF-kappaB signal transduction pathway. Seminars in Cancer Biology, 8, 61 62.
20. Gilmore, T.D. (1999) Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene, 18, 6925 6937.
21. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C.J., Wheatley, K., Burnett, A.K., Goldstone, A.H. Medical Research Council Adult Leukemia Working Party (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukaemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1312 1320.
22. Guinn, B.A., Gilkes, A.F., Woodward, E., Westwood, N.B., Mufti, G.J., Linch, D., Burnett, A.K. Mills, K.I. (2005) Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochemical and Biophysical Research Communications, 333, 703 713.
23. Guttridge, D.C., Albanese, C., Reuther, J.Y., Pestell, R.G. Baldwin, A.S. (1999) NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Molecular and Cellular Biology, 19, 5785 5799.
24. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M. Jordan, C.T. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukaemia cells. Blood, 98, 2301 2307.
25. Guzman, M.L., Rossi, R.M., Karnischky, L., Li, X., Peterson, D.R., Howard, D.S. Jordan, C.T. (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukaemia stem and progenitor cells. Blood, 105, 4163 4169.
26. Guzman, M.L., Rossi, R.M., Neelakantan, S., Li, X., Corbett, C.A., Hassane, D.C., Becker, M.W., Bennett, J.M., Sullivan, E., Lachowicz, J.L., Vaughan, A., Sweeney, C.J., Matthews, W., Carroll, M., Liesveld, J.L., Crooks, P.A. Jordan, C.T. (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukaemia stem and progenitor cells. Blood, 110, 4427 4435.
27. Houldsworth, J., Mathew, S., Rao, P.H., Dyomina, K., Louie, D.C., Parsa, N., Offit, K. Chaganti, R.S. (1996) REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood, 87, 25 29.
28. Huang, S., DeGuzman, A., Bucana, C.D. Fidler, I.J. (2000) Nuclear factor-kappa B activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clinical Cancer Research, 6, 2573 2581.
29. Kaito, K., Kobayashi, M., Sakamoto, M., Shimada, T., Masuoka, H., Nishiwaki, K., Saeki, A., Sekita, T., Otsubo, H. Hosoya, T. (1998) Combination chemotherapy with G-CSF, M-CSF and EPO: successful treatment for acute myelogenous leukaemia without blood transfusion at lower medical costs. Acta Haematologica, 100, 57 60.
30. Karin, M. (1999) How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene, 18, 6867 6874.
31. Karin, M. (2006) NF-kappaB and cancer: mechanisms and targets. Molecular Carcinogenesis, 45, 355 361.
32. Karin, M. Lin, A. (2002) NF-kappaB at the crossroads of life and death. Nature Immunology, 3, 221 227.
33. Kimby, E., Nygren, P. Glimelius, B. (2001) A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncologica, 40, 231 252.
34. Kuper, H., Adami, H.O. Trichopoulos, D. (2000) Infections as a major preventable cause of human cancer. Journal of Internal Medicine, 248, 171 183.
35. López-Franco, O., Hernández-Vargas, P., Ortiz-Muñoz, G., Sanjuán, G., Suzuki, Y., Ortega, L., Blanco, J., Egido, J. Gómez-Guerrero, C. (2006) Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology, 26, 1864 1870.
36. Mathas, S., Jöhrens, K., Joos, S., Lietz, A., Hummel, F., Janz, M., Jundt, F., Anagnostopoulos, I., Bommert, K., Lichter, P., Stein, H., Scheidereit, C. Dörken, B. (2005) Elevated NF-kappa B p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood, 106, 4287 4293.
37. Mayo, M.W. Baldwin, A.S. (2000) The transcription factor NF-kappa B: control of oncogenesis and cancer therapy resistance. Biochimica et Biophysica Acta-Reviews on Cancer, 1470, M55 M62.
38. Meyers, C.A., Albitar, M. Estey, E. (2005) Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukaemia or myelodysplastic syndrome. Cancer, 104, 788 793.
39. Ostermann, H., Rothenburger, M., Mesters, R.M., van de, L.J. Kienast, J. (1994) Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. British Journal of Haematology, 88, 332 337.
40. van der Poll, T., de Jonge, E. Levi, M. (2001) Regulatory role of cytokines in disseminated intravascular coagulation. Seminars in Thrombosis and Hemostasis, 27, 639 651.
41. Rangan, G.K., Wang, Y., Tay, Y.C. Harris, D.C. (1999) Inhibition of NFkappaB activation with antioxidants is correlated with reduced cytokine transcription in PTC. American Journal of Physiology, 277, F779 F789.
42. Ravi, R. Bedi, A. (2004) NF-kappa B in cancer - a friend turned foe. Drug Resistance Updates, 7, 53 67.
43. Romano, M.F., Lamberti, A., Bisogni, R., Tassone, P., Pagnini, D., Storti, G., Del Vecchio, L., Turco, M.C. Venuta, S. (2000) Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukaemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides. Gene Therapy, 7, 1234 1237.
44. Santos, S.C. Dias, S. (2004) Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukaemia through distinct signaling pathways. Blood, 103, 3883 3889.
45. Stifter, S. (2006) The role of nuclear factor kappa B on angiogenesis regulation through monocyte chemotactic protein-1 in myeloma. Medical Hypotheses, 66, 384 386.
46. Turco, M.C., Romano, M.F., Petrella, A., Bisogni, R., Tassone, P. Venuta, S. (2004) NF-kappa B/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukaemia, 18, 11 17.
47. Wang, C.Y., Mayo, M.W. Baldwin, A.S. (1996) TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappa B. Science, 274, 784 787.
48. Wu, M.X., Ao, Z.H., Prasad, K.V.S., Wu, R.L. Schlossman, S.F. (1998) IEX-1L, an apoptosis inhibitor involved in NF-kappa B-mediated cell survival. Science, 281, 998 1001.
49. Zong, W.X., Edelstein, L.C., Chen, C.L., Bash, J. Gelinas, C. (1999) The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappa B that blocks TNF alpha-induced apoptosis. Genes & Development, 13, 382 387.